JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (9): 77-81.doi: 10.6040/j.issn.1671-7554.0.2016.005

Previous Articles     Next Articles

HIV drug resistance and the impact of antiretroviral therapy initiated at different stages among AIDS patiens

YUAN Yuan1, SI Heng1, LIU Hongwei1, LIU Chunhua1, WANG Zhe1, RUAN Yuhua2, XING Hui2   

  1. 1. Institute for AIDS/STD Prevention and Cure, Henan Center for Disease Control and Prevention, Zhengzhou 450016, Hennan, China;
    2. National Center for AIDS/STD Control and Prevention, China CDC, Beijing 102206, China
  • Received:2016-01-04 Online:2016-09-10 Published:2016-09-10

PDF (PC)

238

Abstract: Objective To compare the impact of antiretroviral therapy initiated at different stages on drug resistance among AIDS patients. Methods AIDS patients treated with first-line HAART for 6 months in Henan Province were investigated with cross-sectional survey and blood samples were collected. According to the level of baseline immunology, the patients were divided into 3 groups: early treatment group(n=132, CD4+T cell counts ≥ 350 cell/mm3), conventional treatment group(n=200, 200 cell/mm3 < CD4+T cell counts < 350 cell/mm3)and delayed treatment group(n=329, CD4+T cell counts ≤ 200 cell/mm3). The factors associated with the development of HIV-1 drug resistance were analyzed with multivariate logistic regression. Results A total of 661 patients were investigated. The total prevalence of HIV-1 drug resistance was 34.3%(227/661). The prevalence of drug resistance in the early treatment group, conventional treatment group and delayed treatment group was 21.2%(28/132), 35.5%(71/200)and 38.9%(128/329), respectively. Multivariate logistic regression analysis showed that the protective factors associated with the development of drug resistance included earlier treatment(OR=0.31, 95%CI 0.19-0.51, P<0.001), high compliance(OR=0.48, 95%CI 0.30-0.78, P=0.003)and initiation of ART with 3TC(OR=0.20, 95%CI 0.20- 山 东 大 学 学 报 (医 学 版)54卷9期 -袁源,等.不同时期抗病毒治疗对艾滋病患者耐药产生的影响分析 \=-0.40, P<0.001), while long-duration of treatment(OR=1.90, 95%CI 1.22-2.95, P=0.004 3)was the risk factor. Conclusion Early initiation of antiretroviral therapy for AIDS patients receiving HAART could reduce the emergence of the drug resistant strains and acquire good effect.

Key words: Acquired Immune Deficiency Syndrome, Early initiation of antiretroviral therapy, Influencing factor, Drug resistance

CLC Number: 

  • R183.9
[1] Mwesigire DM, Wu AW, Martin F, et al. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study[J]. BMC Health Serv Res, 2015,15: 292. doi: 10.1186/s12913-015-0959-0.
[2] Hong SY, Jonas A, DeKlerk M, et al. Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia[J]. J Acquir Immune Defic Syndr, 2015, 68(4): 463-471.
[3] Hosseinipour MC, Gupta RK, Van Zyl G, et al. Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings[J]. J Infect Dis, 2013, 207(Suppl 2): S49-56.
[4] Wang J, Wang Z, Liao L, et al. Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China[J]. Sci Rep, 2015, 5: 14823. doi: 10.1038/srep14823.
[5] Liao L, Xing H, Su B, et al. Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China[J]. AIDS, 2013, 27(11): 1815-1824.
[6] Xing H, Ruan Y, Li J, et al. HIV drug resistance and its impact on antiretroviral therapy in Chinese HIV-infected patients[J]. PLoS One, 2013, 8(2): e54917. doi: 10.1371/journal.pone.0054917. Epub 2013 Feb 6.
[7] Kaleebu P, Kirungi W, Watera C. Virological response and antiretroviral drug resistance emerging during antiretroviral therapy at three treatment centers in uganda[J]. PLoS One, 2015, 10(12): e0145536. doi: 10.1371/journal.pone.0145536. eCollection 2015.
[8] 孙定勇, 王奇, 杨文杰, 等. 河南省2003-2009年艾滋病抗病毒治疗患者生存状况分析[J]. 中华流行病学杂志, 2012, 33(2): 181-184. SUN Dingyong, WANG Qi, YANG Wenjie, et al. Survival analysis on AIDS antiretroviral therapy in Henan province during 2003-2009[J]. Chinese Journal of Epidemiology, 2012, 33(2): 181-184.
[9] 杨文杰, 樊盼英, 梁妍, 等. 2008-2013年河南省艾滋病患者抗病毒治疗对HIV的抑制效果及其影响因素分析[J]. 中华预防医学杂志, 2015, 49(1): 13-20. YANG Wenjie, FAN Panying, LIANG Yan, et al. Analysis on HIV suppression effect after initiating antiretroviral treatment and related factors among AIDS patients in Henan province during 2008 and 2013[J]. Chinese Journal of Preventive Medicine, 2015, 49(1): 13-20.
[10] 中国疾病预防控制中心. 国家免费艾滋病抗病毒治疗手册[M]. 3版.北京: 人民卫生出版社, 2012.
[11] Jiamsakul A, Sungkanuparph S, Law M, et al. HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia[J]. J Int AIDS Soc, 2014, 17: 19053. doi: 10.7448/IAS.17.1.19053. eCollection 2014.
[12] 崔卫国, 薛秀娟, 刘佳, 等. 河南省沈丘县抗病毒治疗者HIV耐药株流行状况调查[J]. 中华流行病学杂志, 2013, 34(3): 218-220. CUi Weiguo, XUE Xiujuan, LIU Jia, et al. A cross-sectional study on the prevalence of HIV drug resistance in patients receiving antiretroviral treatment in Shenqiu county, Henan province[J]. Chinese Journal of Epidemiology, 2013, 34(3): 218-220.
[13] Jain V, Byonanebye DM, Amanyire G, et al. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda[J]. AIDS, 2014, 28(15): 2241-2249.
[14] Wang J, He C, Hsi JH, et al. Virological outcomes and drug resistance in Chinese patients after 12 months of 3TC-based first-line antiretroviral treatment, 2011-2012[J]. PLoS One, 2014, 9(2): e88305. doi: 10.1371/journal.pone.0088305. eCollection 2014.
[15] 丁佩佩, 何纲, 陈晓华, 等. 不同CD4+细胞水平HIV感染者抗病毒治疗的疗效及药物不良反应分析[J].中国医师杂志, 2015, 17(1): 52-57. DING Peipei, HE Gang, CHEN Xiaohua, et al. Efficacy and side effects of HAART in HIV-infected patients with different CD4 cell counts[J]. Journal of Chinese Physician, 2015, 17(1): 52-57.
[16] Xing H, Ruan Y, Hsi JH, et al. Reductions in virological failure and drug resistance in Chinese antiretroviral-treated patients due to lamivudine-based regimens, 2003-12[J]. J Antimicrob Chemother, 2015, 70(7): 2097-2103.
[1] GE Li-Juan, JIN Rui-Feng, WANG Ji-Wen, HU Xin-Sheng, LIKun. Association between the C1236T polymorphism in multi-drug resistance gene 1 and response to antiepileptic drug treatment in epileptic patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 99-102.
[2] FAN Jiayin, ZHAO Di, GUO Lei, JIA Liying. Health financing fairness of households in three regions of Shandong Province [J]. Journal of Shandong University (Health Sciences), 2020, 1(9): 89-94.
[3] LI Jiangbing, SONG Xinhong, LIN Haiyan, ZHANG Dongzhi, LI Xiangyi, XU Yibo, WANG Li, XUE Fuzhong. The influencing factors of ischemic ECG abnormalities in a large health check-up population [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(6): 77-81.
[4] MENG Wei, WU Dawei, SHAN Tichao, ZHANG Fan, GUO Haipeng, LIU Yu, DING Shifang, ZHAI Qian. Tigecycline in treating ventilator-associated pneumonia in critically ill patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 71-75.
[5] CHEN Wukang, LÜ Cuixia, ZHANG Xiaofei, DONG Lei, DU Yihui, FU Jihua. Prevalence and influencing factors of methamphetamine use among female sex workers [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(9): 73-76.
[6] GAI Linlin, GUAN Lixue, LI Haibo, CHU Jinjin, ZHU Yun, LI Ming. Screening results and influencing factors of T-SPOT.TB assay in patients with autoimmune rheumatic diseases [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(6): 82-86.
[7] HONG Haijie, SUN Wenjuan, ZHANG Yuan, XU Yongping. Influencing factors of adverse outcomesin term neonates delivered by elective caesarean [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(5): 56-61.
[8] LIU Qiong, PU Yedi, DAI Guangxia, MA Jiale, YANG Jianxia, LI Lizhen, LI Hao, WANG Luqun. A microarray analysis of bortezomib-resistant gene expression in multiple myeloma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(6): 33-38.
[9] WANG Hao, ZHANG Na, XUE Fuzhong, WANG Ping, KANG Dianmin, LIU Yanxun. Spatial epidemiological characteristics of HIV infections and AIDS patients in Shandong Province [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(2): 81-86.
[10] DING Lilu, SUN Qiang. Path analysis for influencing factors of the total health expenditure of China [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(12): 86-89.
[11] LIU Zhenyan, HU Bin, BI Zhenwang, KOU Zengqiang, FANG Ming, CHEN Baoli, REN Yanyan, BI Zhenqiang. Antibiotic resistance on group A streptococcus among children in 4 cities of Shandong Province in 2013 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(1): 77-80.
[12] GUO Bin, WANG Xinhai, XU Lingzhong, GAI Ruoyan. Mental health status and influencing factors in preschoolers in rural areas of Shandong Province [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(1): 87-92.
[13] LI Jianzhuo, JIN Yan, YANG Hui, LI Xinrui, HU Yanxia, ZHANG Changqing, ZHU Yanwen, RUAN Shiman. Influencing factors of drug treatment compliance among patients with HIV/AIDS in Jinan city of China [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(3): 106-110.
[14] LI Ming1, YANG Hua2, GAO Qian-qian1, LI Shi-xue1. Analysis of burden of family long-term caregivers for disabled elders in Jinan city and influencing factors [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(9): 109-112.
[15] XU Yang1, QU Hui2, SUN Guo-rui2, HE Qing-si2. Relationship of the number of all dissected and negative lymph  nodes to the prognosis of patients after pancreatic cancer radical surgery [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(7): 70-74.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd